Efficacy of a Basal-Plus Regimen

Aim: To find out Efficacy of a basal plus regimen. Objectives: 1. To find out the efficacy of basal plus regime by evaluating the changes in HbA1c at 24 weeks. 2. To find out changes in weight and frequency of hypoglycemia after initiation of the basal plus regime. Method: The study was a prospective analysis of 24 weeks after initiation of basal plus regime. Inclusion criteria: T2DMu003e5 Years; On 3OAD + basal insulin, HbA1c- 7.5-8.5%. Exclusion Criteria: critically ill patients, acute infection, pregnant, T1D. All patients matching the inclusion criteria were analyzed on the basis of SMBG chart to find out their highest glycemic excursion of post prandial and fasting readings. Based on the diet recall and sugar reading charts these patients were initiated on bolus insulin with the largest meal of the day where their post prandial corresponded to the highest reading. They were educated on proper insulin injection techniques and SMBG and asked to follow-up with their sugar readings using telemedicine application every day. Result: We studied 220 patients (F=124 M=96) with HbA1c at baseline 7.5-8.5% (avg-8.0). After addition of bolus insulin at 12 weeks target HbA1c Conclusion: After failure of OADS and basal insulin a basal plus regime with addition of 1 bolus insulin with the largest meal of the day helped achieve the target HbA1c of Disclosure B.D.J. Saboo: None. D. Hasnani: None. H. Chandarana: None. S. Bhandari: None. S. Joshi: None. J. Kesavadev: Advisory Panel; Self; Novo Nordisk India Private Limited. Speaker9s Bureau; Self; Novo Nordisk India Private Limited. Advisory Panel; Self; Medtronic. Speaker9s Bureau; Self; Medtronic. Advisory Panel; Self; Sanofi. Speaker9s Bureau; Self; Sanofi. Research Support; Self; MSD. Speaker9s Bureau; Self; MSD. Advisory Panel; Self; AstraZeneca. Speaker9s Bureau; Self; AstraZeneca. A. Maheshwari: None. H. Thacker: Research Support; Self; Wockhardt LTD.